Utility of Drosophila for studying hypoxia-inducible factor (HIF) in neurodegenerative diseases: Advantages versus limitations.
Utility of Drosophila for studying hypoxia-inducible factor (HIF) in neurodegenerative diseases: Advantages versus limitations.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Kyiv, UA · Author affiliation
Chebotarev State Institute of Gerontology, National Academy of Medical Sciences of Ukraine, Kyiv 04114, Ukraine. Electronic address: serebrovska@geront.kiev.ua.Location evidence
US · Author affiliation · country only
Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA. Electronic address: lei.xi@vcuhealth.org.Location evidence
Shevchenko, UA · Author affiliation
Institute of Biology and Medicine, Taras Shevchenko National University of Kyiv 03127, Ukraine.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Hypoxia-inducible factor 1α (HIF-1α) plays a critical role in cellular responses to oxygen deprivation and is increasingly recognized as a key regulator in neurodegenerative diseases. Drosophila melanogaster serves as a powerful genetic model for investigating HIF-1α signaling, particularly through its homolog Sima. This review examines the advantages and limitations of using Drosophila to study HIF-1α in the context of neurodegeneration, with a focus on oxidative stress, autophagy, and mitochondrial dysfunction. We discuss the role of HIF-1α/Sima in modulating neuroprotective pathways, including its interactions with DJ-1 (also known as PARK7 Parkinson disease protein 7), SNCA (Alpha-synuclein), and the mTOR-autophagy axis. Moreover, we highlight the potential of Drosophila in elucidating hypoxia-mediated epigenetic modifications, non-coding RNA regulation, and metabolic adaptations relevant to neurodegenerative diseases. Understanding these mechanisms may provide insights into novel therapeutic approaches for the major neurodegenerative conditions in humans, such as Parkinson's disease and Alzheimer's disease.